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Background: Recent studies have established the role of Rho-kinase in the pathophysiology of cardiovascular diseases including vascular 
inflammation and fibrosis. Diabetes is a major risk factor for left ventricular dysfunction as well as cardiac and renal fibrosis. We examined the 
antifibrotic and cardio-humoral effects of Rho-kinase inhibition (fasudil) in a rat model of diabetes mellitus (DM).
Methods: DM was induced in male Wistar rats by injecting Streptozotocin (65 mg/Kg). Four weeks after establishing diabetes, the treatment group 
(n=5) received a suspension of fasudil daily by gavage for two months at 100mg/kg/day and the DM control group (n=6) received no treatment. A 
non-diabetic group (n=6) was maintained as a positive control. Plasma humoral profile was assessed at 3 months. Myocardial and kidney tissues 
were sectioned and stained to assess the infiltration of collagen III. (** p< 0.01,* p< 0.05)
Results: There was a significant** increase in LV collagen III infiltration in DM rats (17.7%±3) as compared to non-DM controls (1.6%±0.3). 
Fasudil treated rats showed significant** reduction in LV collagen III infiltration (4.6±0.3). Renal cortical fibrosis was also significantly** reduced 
(0.92%±0.3 vs. 6.8%±0.9) in fasudil group compared to DM rats and was similar to non-DM controls (0.79%±0.2). DM rats displayed systolic 
and diastolic myocardial dysfunction as compare to non-DM controls, determined by peak circumferential contraction strains (Cs-C) (10.4 ±0.6 
vs14.3 ±0.6 %*), strain rate (Csr-C) (2.3 ±0.1 vs.3.9 ±0.2 s-1*) and early diastolic strain rates (Csr-E) (2.6 ±0.2 vs.3.9 ±0.3 s -1*). LV dysfunction 
improved significantly*with fasudil treatment. There was a decrease in plasma BNP*, renin*, and aldosterone* levels with fasudil as compared to 
the DM rats.
Conclusions: DM results in LV dysfunction, with significant infiltration of collagen III in the LV and kidney cortex. Fasudil treatment reduced fibrosis 
and improved LV systolic and diastolic myocardial function with suppression of aldosterone and renin. These findings suggest that a Rho-kinase 
inhibitor has potent cardiorenal antifibrotic effects in DM.
